Continued research regarding mesothelioma and the link to asbestos exposure is necessary if we ever hope to find a cure.  Imagine someone you love returning home from the second world war.  They find a job as an auto mechanic, raise a family, and play by the rules.  Decades later, they tragically die from mesothelioma cancer because someone failed to warn them of the dangers of asbestos fibers.   Does any reasonable person believe this is fair or just?   Of course not.  Unfortunately, we cannot go back in time and prevent the asbestos exposure.  But what we can do is try to promote public awareness about this deadly disease and highlight some of the great research being done.

One interesting study is called, "Malignant mesothelioma: attributable risk of asbestos exposure." By R Spirtas, E F Heineman, L Bernstein, G W Beebe, R J Keehn, A Stark, B L Harlow, and J Benichou - Occup Environ Med 1994;51:804-811 doi:10.1136/oem.51.12.804.  Here is an excerpt:

Read more »

The U.S. National Institutes of Health (NIH) a free digital archive of biomedical and life sciences journal literature defines pericardial mesothelioma as a type of cancer that originates in the mesothelium, a thin wall of cells that surround the body's organs and internal body structures. Pericardial mesothelioma originates in the lining of the heart. Other locales of the disease are malignant pleural mesothelioma, which occurs in the lining of the lungs and malignant peritoneal mesothelioma, which occurs in the abdomen wall. Pericardial mesothelioma is the rarest of the types of mesothelioma and accounts for only a small percent of the two thousand to three thousand mesothelioma cases that are diagnosed each year.

Pericardial Mesothelioma and Exposure To Asbestos
Read more »

Pemetrexed under brand name Alimta is a form drug manufactured by Eli Lily and Company. Its purpose to treat maligant pleural mesothelioma and non small cell lung cancer.

In 2004, United States Food and Drug Administration approved the drug for the treatment of malignant pleural mesothelioma (MPM), in combination with cisplatin. In 2008 FDA approved as first line treatment in combination with cisplatin, against of locally-advanced and metastatic non-small cell lung cancer.
Maligant pleural mesothelioma is relatively a mainstream cancer, with only an approximate 2,000 new cases each year. Whose incidence is expected to increase in the, Western Europe, United Kingdom and Australia over the next 20 years. MPM is usually linked previously exposure to asbestos. When asbestos fibres are swallowed or inhaled, they can cause scarring of the lung tissues, cancer of the bronchial tree and sometimes cancers in the peritoneum and pleura.

Read more »

Tags: mesothelioma-lawyer, health-and-wellness, mesothelioma fibrosis lmesothelioma, houston mesothelioma